Menu
Recruiting NCT06121466

Effect of Abdominal Wall Injections on Abdominal Pain

Phase IV Interventional Anterior Cutaneous Nerve Entrapment Syndrome

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Abdominal wall injections with lidocaine 2%.
Who it may be relevant to
Registry conditions: Anterior Cutaneous Nerve Entrapment Syndrome. Basic parameters: 18 years — 100 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This is a prospective cohort study of outpatient adults with chronic abdominal wall pain receiving abdominal wall injections, as part of their usual care, with lidocaine. Subjects will be recruited at the outpatient gastroenterology clinic at OHSU.

Detailed description

This is a prospective cohort study of outpatient adults with chronic abdominal wall pain who receive abdominal wall injections with lidocaine at an academic medical center. Thirty patients will be enrolled. A baseline assessment will include a medical history review and survey administration (Pain Catastrophizing Scale, Psychological Inflexibility in Pain Scale, Patient-Reported Outcomes Measurement Information System-29, Recurrent Abdominal Pain Intensity and Disability scale). Subjects will undergo Quantitative Sensory Testing to measure their pain tolerance and thresholds. The primary outcome to be measured is the change in abdominal wall pain at 1 week, 4 weeks and 12 weeks following the abdominal wall injection, with improvement defined as a 50% reduction in baseline pain score measured using an 11-point numeric scale. Data analysis will consist of basic summary statistics to describe the mean, median, and standard deviation for demographic variables and clinical measures. A one-sample t-test or Wilcoxon test will be used to compare differences in continuous values between time points. Chi-square tests will be used to compare differences in categorical variables. An alpha of 0.05 will be used for all statistical tests. Univariate and multivariate logistic regression will be used to assess for factors associated with pain reduction.

Interventions

  • Drug Abdominal wall injections with lidocaine 2%
    Injections will be administered for patient who are identified as having abdominal wall pain.

Primary outcome measures

  • 1) To measure the change in abdominal wall pain 1-week, 1-month and 3-months following abdominal wall injections, with improvement defined as a 50% reduction in baseline pain score measured using an 11-point numeric scale. [Time frame: 12 weeks]
  • 2) To determine patient characteristics, such as pain catastrophizing, associated with a response to abdominal wall injection [Time frame: 12 weeks]
  • 2) To determine patient characteristics, such as patient reported functional status, pain status, and global estimate status; associated with a response to abdominal wall injection [Time frame: 12 weeks]
  • 2) To determine patient characteristics, within seven health domains, associated with a response to abdominal wall injection [Time frame: 12 weeks]
  • 2) To determine patient characteristics, such as psychological inflexibility, associated with a response to abdominal wall injection [Time frame: 12 weeks]
  • 3) To determine the rate of adverse events associated with abdominal wall injection. [Time frame: 12 weeks]
  • 4) To measure pain thresholds with use of heat, using quantitative sensory testing (QST) in patients receiving abdominal wall injections. [Time frame: 12 weeks]
  • 4) To measure pain thresholds with use of temporal summation, using quantitative sensory testing (QST) in patients receiving abdominal wall injections. [Time frame: 12 weeks]
  • 4) To measure pain thresholds with use of pressure thresholds, using quantitative sensory testing (QST) in patients receiving abdominal wall injections. [Time frame: 12 weeks]

Eligibility criteria

Inclusion criteria

  • Localized abdominal wall pain
  • Average daily pain (7-day recall) ≥ 3 on a scale of 0-10
  • Suspected abdominal wall etiology for abdominal pain
  • Positive Carnett's sign or pain near an incisional site
  • 18 years of age or older

Exclusion criteria

  • Suspected visceral etiology for the abdominal pain
  • Severe allergy to lidocaine
  • Unwillingness or inability to provide informed consent
  • Low probability of follow-up
  • Abdominal wall hernia noted at the point of pain
  • History of trigger point injections for abdominal pain
  • Bleeding disorder
  • Pregnancy, incarceration or decisionally impaired

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 2 centers
  • OHSU — Portland
  • Oregon Health Sciences University — Portland

Identifiers

NCT: NCT06121466 · STUDY00024914

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗